Vascular effects of biologic agents in RA and spondyloarthropathies (Q37630351)

21 August 2017

1 reference

title

Vascular effects of biologic agents in RA and spondyloarthropathies (English)

1 reference

21 August 2017

Zoltán Szekanecz

1

1 reference

21 August 2017

György Kerekes

series ordinal

2

1 reference

21 August 2017

Pál Soltész

series ordinal

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

10 November 2009

1 reference

Nature Reviews Rheumatology

21 August 2017

published in

1 reference

21 August 2017

volume

5

1 reference

21 August 2017

issue

12

1 reference

21 August 2017

page(s)

677-684

1 reference

The roles of cytokines, inflammation and immunity in vascular diseases

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Accelerated atherosclerosis in autoimmune rheumatic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Accelerated atherosclerosis in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Cardiovascular risk in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Cardiovascular disease in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Vascular involvement in rheumatic diseases: 'vascular rheumatology'.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Atherosclerosis — An Inflammatory Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Mechanisms of disease: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Role of inflammation in atherosclerosis associated with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Role for TNF in atherosclerosis? Lessons from autoimmune disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Interleukin-8 and tumor necrosis factor-alpha are involved in human aortic endothelial cell migration. The possible role of these cytokines in human aortic aneurysmal blood vessel growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

The contribution of adipose tissue and adipokines to inflammation in joint diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Anti-inflammatory and anti-atherogenic effects of adiponectin in patients with rheumatoid arthritis following anti-TNF therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Augmentation index and large-artery remodeling in patients with longstanding rheumatoid arthritis compared with healthy controls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Cardiovascular risks in spondyloarthritides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Impaired endothelial function in patients with ankylosing spondylitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Infliximab improves vascular stiffness in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Anti-tumour necrosis factor agents and lipid profile: a class effect?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Etanercept increases adiponectin level in woman with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Effect of etanercept on insulin sensitivity in nine patients with psoriasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2009.219

Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis

31 March 2020

1 reference

12 December 2020

Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis

1 reference

12 December 2020

Myocardial performance and aortic elasticity are impaired in patients with ankylosing spondylitis

1 reference

12 December 2020

Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab

1 reference

12 December 2020

Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

1 reference

12 December 2020

Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis.

1 reference

12 December 2020

Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis.

1 reference

12 December 2020

Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis

1 reference

12 December 2020

Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity.

1 reference

12 December 2020

Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis

1 reference

12 December 2020

The serum levels of resistin in rheumatoid arthritis patients

1 reference

12 December 2020

Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab

1 reference

12 December 2020

Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis

1 reference

12 December 2020

Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2009.219

1 reference

release_f24ufkt5xvda5jiovha33yt7k4

21 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/f24ufkt5xvda5jiovha33yt7k4

24 November 2022

mapped directly with Wikidata item

1 reference